- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06147505
Natural Killer (NK) Cells (XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)
February 1, 2024 updated by: Dushu Lake Hospital Affiliated to Soochow University
Clinical Study of Evaluating the Safety and Initial Efficacy of XS005 Cell Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma
The main objective of this clinical study is to evaluate the safety of XS005 cell which contains Natural Killer (NK) cells and culture-expanded injection; to determine the maximum tolerated dose .
Furthermore, initial efficacy will be examined.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Treatment on this study includes eight XS005 cell infusions over an 16 week period.
The study will evaluate the safety, feasibility and maximum tolerated dose (MTD) of XS005 cell using a 3+3 study design .
The total study duration will be 2 years.
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yulun Huang
- Phone Number: +86 130 1388 9432
- Email: huangyulun@suda.edu.cn
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215125
- Recruiting
- Dushu Lake Hospital Affiliated to Soochow University
-
Contact:
- Yulun Huang
- Phone Number: +86 130 1388 9432
- Email: huangyulun@suda.edu.cn
-
Contact:
- Xuetao Li
- Phone Number: +86 151 9563 7789
- Email: lixuetao0405@126.com
-
Principal Investigator:
- Yulun Huang
-
Sub-Investigator:
- Xuetao Li
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age between 18 and 70 years old (including the threshold), both male and female;
- GBM (2021 5th Edition of World Health Organization(WHO) Classification of Central nervous System Tumors) diagnosed for the first time by imaging and histopathology;
- Expected survival ≥6 months;
- Karnofsky performance status(KPS) score ≥60 before treatment;
The level of organ and bone marrow function must meet the following requirements:
- Bone marrow: Absolute neutrophil count (ANC) ≥1.5×109/L, platelet count ≥100×109/L, hemoglobin ≥90g/L, and no platelet or red blood cell transfusion within 14 days prior to first administration. And did not receive blood transfusion or biological response regulators (such as granulocyte growth factor, erythrocyte growth factor, interleukin-11, etc.) within 14 days before the first administration;
- Liver function: No history of cirrhosis (Child-Pugh grade B, C). Serum total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN;
- Renal function: serum creatinine ≤1.5×ULN, or creatinine clearance ≥50ml/min (Cockcroft-Gault formula); Qualitative urine protein ≤1+; If the qualitative urine protein is ≥2+, it is necessary to conduct a quantitative urine protein test for 24 hours. According to the examination results, the researchers made the admission judgment.
- Coagulation function: prothrombin time (PT) ≤1.5×ULN; International standardized ratio (INR) ≤1.5×ULN, and activated partial thromboplastin time (APTT) ≤1.5×ULN (except those receiving therapeutic anticoagulants);
- The subjects (including male subjects) have no pregnancy plan and voluntarily take effective contraceptive measures during the screening period and from the beginning of the study administration to the last dose of the study drug within 6 months after the study drug is administered, and have no sperm or egg donation plans, in which the study period should voluntarily take effective contraceptive measures;
- Able to understand the procedures and methods of this study, willing to sign informed consent and strictly follow the clinical study protocol to complete this study.
Exclusion Criteria:
- Patients who received other anti-tumor drugs (including chemotherapy, targeted drugs other than bevacizumab, immunotherapy, Chinese medicine anti-tumor therapy, etc.) except for patients who received concurrent radiotherapy and chemotherapy for GBM after surgery (TMZ dosage ≤75mg/m2, radiotherapy dose limited to 50-60Gy);
- Previous or current malignant tumors of other types, except for the following cases: basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin or cervical cancer in situ;
- Known to be allergic to dacarbazine, temozolomide, the investigational drug, or any of its excipients, or has had a history of unexplained severe allergic reactions;
- The presence of any contraindications to MRI, such as: use of a pacemaker, infusion pump, or allergy to MRI contrast agents;
- Receive live attenuated vaccine or vaccine within 4 weeks prior to the first study drug treatment or plan to receive live vaccine during the study period;
- Subjects with active or pre-existing autoimmune diseases that are likely to recur, or patients at high risk (such as those who have received an organ transplant and require immunosuppressive therapy).
- Severe cardiovascular and cerebrovascular diseases within 6 months before screening;
- Patients with sudden lung disease, interstitial lung disease or pneumonia, pulmonary fibrosis, acute lung disease, etc., which cannot be controlled after treatment, except local interstitial pneumonia induced by radiotherapy;
- A history of infection with human immunodeficiency virus, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation or stem cell transplantation; Except for those that do not require immunosuppressive therapy, such as corneal transplantation;
Evidence of active infection:
- Hepatitis B (with hepatitis B surface antigen(HBsAg) positive, hepatitis B virus-DNA(HBV-DNA)≥500IU/ml and abnormal liver function);
- Hepatitis C (hepatitis C antibody( HCV-Ab) positive, hepatitis C virus-RNA(HCV-RNA) higher than the lower limit of assay and abnormal liver function);
- Patients with active pulmonary tuberculosis infection found through medical history or CT examination, or a history of active pulmonary tuberculosis infection within 1 year before enrollment, or a history of active pulmonary tuberculosis infection more than 1 year ago without formal treatment;
- Have a clear history of neurological or psychiatric disorders, or a known history of psychotropic substance abuse, alcohol abuse, or drug use;
- Received any investigational drug within 4 weeks prior to initial dosing, or participated in another clinical study at the same time;
- Women who are pregnant or breastfeeding, or who have a positive baseline pregnancy test;
- Patients deemed unsuitable for inclusion in this study by the investigators.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
Subjects With Primary Glioblastoma
|
Treatment on this study includes eight XS005 cell infusions over an 16 week period. Phase 1: dose escalation (3+3); Phase 2 : dose of recommended phase 2 dose(RP2D).
Other Names:
Patients were given temozolomide on day 1 to day 5 of each cycle, 28 days per cycle, for a total of 4 cycles.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Dose-Limiting Toxicities (DLTs)
Time Frame: within 7 days after the the first infusion of XS005.
|
DLT is defined as a toxic effect in the subject at any dose, cannot be reasonably attributed to the subject's underlying disease, other conditions, and/or concomitants, that the investigator determines to be related (including definitely, likely, or possibly) to the XS005 cell injection.
|
within 7 days after the the first infusion of XS005.
|
Incidence of Adverse Events (AEs)
Time Frame: 4 months
|
AE is defined as any adverse medical event within 4 months after the the first infusion of XS005.
|
4 months
|
Maximum tolerated dose (MTD)
Time Frame: within 7 days after the the first infusion of XS005.
|
MTD is defined as the highest dose level of less than or equal to 2 DLT among the 6 subjects finally determined.
|
within 7 days after the the first infusion of XS005.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: From the start of treatment until the time of first disease progression or death , assessed up to 12 months post-treatment
|
PFS : defined as the time from the start of treatment until the onset of tumor progression or death from any cause;
|
From the start of treatment until the time of first disease progression or death , assessed up to 12 months post-treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of natural killer (NK ) cells in cerebrospinal fluid(CSF).
Time Frame: Day 2 to day 9 of each treatment cycle(each treatment cycle is 28 days).
|
Changes of NK cells in CSF pre-and post- infusion and at each of the main follow-up time points.
|
Day 2 to day 9 of each treatment cycle(each treatment cycle is 28 days).
|
Changes of cytokines in CSF.
Time Frame: Day 2 to day 9 of each treatment cycle(each treatment cycle is 28 days).
|
Changes of cytokines (such as interleukin-6(IL-6), interferon-γ (IFN-γ) etc.) in CSF pre-and post- infusion and at each of the main follow-up time points.
|
Day 2 to day 9 of each treatment cycle(each treatment cycle is 28 days).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 29, 2023
Primary Completion (Estimated)
November 2, 2025
Study Completion (Estimated)
December 29, 2025
Study Registration Dates
First Submitted
November 8, 2023
First Submitted That Met QC Criteria
November 23, 2023
First Posted (Actual)
November 27, 2023
Study Record Updates
Last Update Posted (Estimated)
February 5, 2024
Last Update Submitted That Met QC Criteria
February 1, 2024
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Temozolomide
Other Study ID Numbers
- XS-005
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on XS005 Cell Injection
-
Royan InstituteCompletedBone CystIran, Islamic Republic of
-
Royan InstituteCompletedNonunion FracturesIran, Islamic Republic of
-
Royan InstituteCompletedOsteoarthritisIran, Islamic Republic of
-
Xspray Pharma ABCompletedPharmacokinetics | BioavailabilityUnited Kingdom
-
Changzhou No.2 People's HospitalNot yet recruiting
-
Texas Plastic SurgeryUnknown
-
Peking UniversityNot yet recruiting
-
Royan InstituteCompletedLeg Length InequalityIran, Islamic Republic of
-
Beijing Boren HospitalTerminatedAdvanced Solid Tumor | Relapsed/Refractory LymphomaChina
-
Imbioray (Hangzhou) Biomedicine Co., Ltd.The First Affiliated Hospital of Soochow UniversityNot yet recruiting